2nd Quarter - Report

ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.

Period 2nd Quarter 2022 Filed Jul 20, 2022 Signed by John Thomas Graves Jr.

Official filing
Firm
ERVIN GRAVES STRATEGY GROUP, LLC
Client
EMERGENT BIOSOLUTIONS INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone House and Senate appropriations for FY 2023 H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act

LobbyistCovered position, as disclosed
JAMES L ERVIN —
COLBY MILLER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS)

Bills named: S. 987 (117th), H.R. 5224 (117th), H.R. 2366 (117th), H.R. 3263 (117th), H.R. 2379 (117th), H.R. 4341 (117th), S. 3799 (117th), H.R. 7681 (117th), S. 1457 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.